Skip to main content
Erschienen in: Reactions Weekly 1/2023

01.12.2023 | Case report

Ipilimumab/Nivolumab

Grade 1 hypothyroidism and grade 3 secondary adrenal insufficiency

Erschienen in: Reactions Weekly | Ausgabe 1/2023

Einloggen, um Zugang zu erhalten

Excerpt

Author Information
An event is serious (based on the ICH definition) when the patient outcome is:
  • * death
  • * life-threatening
  • * hospitalisation
  • * disability
  • * congenital anomaly
  • * other medically important event
Literatur
Zurück zum Zitat Kedarisetti S, et al. Did You Follow Your Patient After ICI Cessation? A Case of Immune-Related Adverse Event 5 Months Following Completion Of Immunotherapy. Journal of the Endocrine Society 6 (Suppl. 1): A865-A866 abstr. LBODP108, Nov 2022. Available from: URL: https://dx.doi.org/10.1210/jendso/bvac150.1790 [abstract] Kedarisetti S, et al. Did You Follow Your Patient After ICI Cessation? A Case of Immune-Related Adverse Event 5 Months Following Completion Of Immunotherapy. Journal of the Endocrine Society 6 (Suppl. 1): A865-A866 abstr. LBODP108, Nov 2022. Available from: URL: https://​dx.​doi.​org/​10.​1210/​jendso/​bvac150.​1790 [abstract]
Metadaten
Titel
Ipilimumab/Nivolumab
Grade 1 hypothyroidism and grade 3 secondary adrenal insufficiency
Publikationsdatum
01.12.2023
Verlag
Springer International Publishing
Erschienen in
Reactions Weekly / Ausgabe 1/2023
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI
https://doi.org/10.1007/s40278-023-51042-y

Weitere Artikel der Ausgabe 1/2023

Reactions Weekly 1/2023 Zur Ausgabe

Case report

Insulin-glargine

Case report

Prednisolone

Case report

Allopurinol

Case report

Rituximab